# A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

> **NCT06361888** · PHASE2,PHASE3 · RECRUITING · sponsor: **Hutchmed** · enrollment: 502 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
- **DRUG:** Nab-paclitaxel Plus Gemcitabine
- **DRUG:** Surufatinib with Nab-paclitaxel, and Gemcitabine

## Key facts

- **NCT ID:** NCT06361888
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 502 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361888, "A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06361888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*